Deliver
“medicines that matter”
for patients
News
Mission
Deliver “medicines that matter” to improve patient health and contribute to enhanced quality of life. At ARTham Therapeutics, we will create value by developing innovative medicines that are disease modifying and improve patient health.
Value
ARTham Therapeutics Inc., is a clinical stage biopharmaceutical company that will deliver ‘medicines that matter’ for patients. Our goal is to create innovative medicines that are disease modifying and satisfy significant unmet medical need. To deliver on cost and time efficiency, ARTham will run a virtual R&D operating model that seeks innovation through the best academic and business partners.
Teams
Management team
Scientific Leadership
Directors
Investors
- Other：Takeda Pharmaceutical Company Limited
Unravel hidden value
and deliver drugs that
ultimately help patients
Science
Pipline
ART-648
Orally available phosphodiesterase type 4 (PDE4) inhibitor
- Broad spectrum anti-inflammatory effects via intracellular cAMP increase
- Preclinical validation of anti-fibrotic and anti-obesity effects
- Opportunities to treat dermal (bullous pemphigoid, psoriatic arthritis),
metabolic (NASH) and respiratory (COPD, IPF) disorders with high unmet medical needs - Optimal pharmacokinetic and safety/tolerability profile demonstrated in Phase 1 clinical study in healthy subjects
Indication: Bullous Pemphigoid
- A rare autoimmune chronic skin disorder resulting in generalized, pruritic, bullous lesions
- Autoantibodies recognize components of the basement membrane zone called BP180 and BP230
- Primarily a geriatric dermal disorder that occurs in patients aged >70 years
- Usually starts with redness and itching of the skin, and within weeks to months, thin-walled, tense blisters appear
over whole body - Mucous membranes may also be involved, but less common
- Topical and systemic corticosteroids as standard cares for patients with moderate-severe conditions
- Prevalence in the US: 12 /100,000 adults; 38/100,000 adults aged ≥60 years (Wertenteil et al., 2018)
- ~7,000 patients in Japan (Japan Intractable Diseases Information Center); ~20,000 patients including patients with mild symptoms
- R&D grant from the Japan Agency for Medical Research and Development (AMED) Program for Orphan Drugs prior
to Designation awarded since FY2020 - Phase 2 study to be initiated in 1H FY2021 (Japan Fiscal Year: April 1st to March 31st)
Indication: COVID-19
- Potential novel pharmacotherapy to prevent developing severe pneumonia in COVID-19 patients with
mild to moderate conditions and long term lung tissue damage leading to fibrosis - Prevent cytokine storm by anti-inflammatory effects via various types of inflammatory and immune cells
- Active collaboration with National Center for Global Health & Medicine, Timewell Medical Inc., and Oita University
- AMED R&D grant awarded since FY2020
- Phase 2 study to be initiated in 1H FY2021
ART-001
New Effective Treatment for Vascular Malformations
ART-001: First in Class PI3K (phosphatidylinositol-3-kinase) inhibitor for
the treatment of vascular malformations and overgrowth syndromes
- Significant unmet medical need with no current pharmacotherapy
- Patient with GOF mutation of PI3K-AKT pathway
- Selective inhibition of angiogenesis
- This program has received a grant from AMED, Japanese Agency for Medical Research and Development.
Vascular malformations are benign (non-cancerous) lesions that are present at birth,
but may become visible for weeks or months after birth. Unlike hemangiomas, vascular malformations
do not have a growth cycle and then regress but instead continue to grow slowly throughout life.
Most vascular malformations are sporadic (occurring by chance),
though some are inherited in a family as an autosomal dominant trait.
ART-002
under preparation
